This paper investigates the importance of cardiac biomarkers and echocardiography in risk assessment in patients with venous thromboembolic disease. The paper is based on the analysis of deep vein thrombosis, pulmonary embolism, hepatic vein thrombosis and cerebral vein disease, providing an overview of the treatment and prophylaxis of venous thromboembolic disease. Cardiac biomarkers, such as brain natriuretic peptide and cardiac troponins, provide important information about myocardial injury, and right ventricular dysfunction, which are common complications in patients with venous thromboembolic disease. Incorporating cardiac biomarkers into risk stratification models can help differentiate low-, intermediate-, and high-risk patients and guide treatment decisions, in order to improve outcomes. Echocardiography, as a key imaging method in assessing cardiac function in venous thromboembolic disease, plays an important role in identifying the severity of pulmonary embolism. This non-invasive technique enables visualization of the heart and assessment of right ventricular function and pressure overload. Identification of right ventricular enlargement and/or hypokinesia by echocardiography may indicate an increased risk in pulmonary embolism. The presence of right ventricular dysfunction on echocardiography is associated with a higher risk of short-term mortality, which may influence the choice of therapy. In conclusion, the integration of cardiac biomarkers and echocardiography is essential in risk assessment in patients with venous thromboembolic disease. These diagnostic tools provide important insights into cardiac function, hemodynamic status, and prognosis, helping clinicians stratify patients according to their risk and optimize the therapeutic approach to improve outcomes.